Table 5.
Results of cohort studies
| IG | CG | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| References | Variable | Baseline | End of treatment | Follow-up | P | Baseline | End of treatment | Follow-up | P |
| Bukowska et al, 201526 | a | – | 62.2 ± 1.5 | – | <.001 | – | 63.2 ± 2.0 | – | .131 |
| b | – | 37.8 ± 1.5 | – | <.001 | – | 36.9 ± 2.0 | – | .056 | |
| c | – | 12.3 ± 1.5 | – | <.001 | – | 13.2 ± 2.1 | – | .065 | |
| d | – | 1.0 ± 0.1 | – | <.001 | – | 1.1 ± 0.1 | – | .438 | |
| e | – | 116.6 ± 9.1 | – | .001 | – | 113.1 ± 12.8 | – | .545 | |
| f | – | 0.5 ± 0.1 | – | <.001 | – | 0.5 ± 0.1 | – | .035 | |
| g | – | 1.2 ± 0.2 | – | <.001 | – | 1.1 ± 0.2 | – | .03 | |
| h | – | 1.2 ± 0.2 | – | <.001 | – | 1.1 ± 0.2 | – | .038 | |
| i | – | 0.2 ± 0.0 | – | .172 | – | 0.2 ± 0.0 | – | .107 | |
| Pau et al, 201627 | f | 0.5 ± 0.1 | 0.6 ± 0.1 | 0.6 ± 0.1 | <.001 | – | – | – | – |
| g | 1.1 ± 0.3 | 1.2 ± 0.3 | 1.2 ± 0.3 | <.001 | – | – | – | – | |
| e | 114.6 ± 13.4 | 120.8 ± 9.4 | 120.6 ± 12.3 | .024 | – | – | – | – | |
| i | 0.2 ± 0.0 | 0.2 ± 0.0 | 0.2 ± 0.1 | <.001 | – | – | – | – | |
| a | 61.1 ± 2.8 | 59.4 ± 3.1 | 60.1 ± 2.0 | .002 | – | – | – | – | |
| b | 38.7 ± 2.6 | 40.3 ± 2.5 | 39.9 ± 2.0 | .004 | – | – | – | – | |
| c | 11.6 ± 2.6 | 10.2 ± 2.1 | 10.2 ± 2.0 | .002 | – | – | – | – | |
| IG1 | IG2 | CG | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| References | Variable | Baseline | End of treatment | Follow-up | P | Baseline | End of treatment | Follow-up | P | Baseline | End of treatment | Follow-up | P |
| Agosta et al, 2017∗25 | j | 2.3 ± 0.4 | 2.4 ± 0.4 | 2.2 ± 0.4 | .9 | 2.2 ± 0.3 | 2.2 ± 0.3 | 2.2 ± 0.4 | 1 | - | - | - | - |
| k | 27.6 ± 9.7 | 23.3 ± 7.8 | 23.3 ± 10.1 | .05 | 23.5 ± 7.9 | 24.2 ± 8.3 | 22.1 ± 8.4 | .59 | - | - | - | - | |
| l | 11.7 ± 2.9 | 9.7 ± 3.4 | 10.2 ± 2.4 | .02 | 12.6 ± 3.8 | 10.9 ± 3.0 | 11.3 ± 3.0 | .05 | - | - | - | - | |
| m | 1.3 ± 1.0 | 1.2 ± 0.9 | 0.9 ± 0.9 | .36 | 1.0 ± 0.9 | 1.3 ± 0.8 | 0.9 ± 1.0 | .35 | - | - | - | - | |
| n | 24.7 ± 11.1 | 19.0 ± 9.2 | 17.0 ± 7.0 | .02 | 20.2 ± 11.6 | 14.0 ± 8.9 | 16.7 ± 10.5 | .02 | - | - | - | - | |
| o | 50.9 ± 3.8 | 53.6 ± 2.6 | 53.4 ± 2.7 | .002 | 52.2 ± 4.3 | 54.4 ± 2.4 | 54.4 ± 2.2 | .06 | - | - | - | - | |
| p | 9.0 ± 1.7 | 8.2 ± 1.1 | 8.2 ± 1.4 | .03 | 8.0 ± 1.8 | 7.2 ± 1.2 | 7.7 ± 1.7 | .03 | - | - | - | - | |
| q | 6.6 ± 1.8 | 6.0 ± 1.4 | 6.1 ± 2.0 | .01 | 6.3 ± 1.4 | 5.6 ± 1.0 | 6.0 ± 1.6 | .01 | - | - | - | - | |
- = unspecified information; CG = control group; IG = intervention group; P = significance level; a = support phase; b = balance phase, c = double support phase, d = stride time; e = cadence; f = step length, g = speed; h = stride length; i = stride width; j = Hoehn e Yahr Scale mode ON; k = Unified Parkinsons Disease Rating Scale—Part III mode ON; l = Freezing of Gait Questionnaire; m = Unified Parkinsons Disease Rating Scale—Part II (Freezing of Gait Questionnaire) mode ON; n, Parkinsons Disease Questionnaire; o = Berg Balance Scale; p = walking test at a distance of 10 m at comfortable speed; q = walking test at a distance of 10 m at maximum speed.
∗The article of Agosta et al (2017) presents 2 IGs, requiring a different table from the other cohort studies.